Steve Miller Sells 50,000 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) insider Steve Miller sold 50,000 shares of the business’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the sale, the insider now directly owns 686,996 shares in the company, valued at $15,065,822.28. This trade represents a 6.78 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ CPRX opened at $21.34 on Friday. Catalyst Pharmaceuticals, Inc. has a one year low of $13.12 and a one year high of $24.27. The firm has a market cap of $2.55 billion, a price-to-earnings ratio of 18.08, a P/E/G ratio of 3.36 and a beta of 0.75. The stock’s fifty day moving average price is $21.59 and its two-hundred day moving average price is $19.10.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. Susquehanna Fundamental Investments LLC bought a new position in shares of Catalyst Pharmaceuticals in the second quarter worth $258,000. Integral Health Asset Management LLC acquired a new position in shares of Catalyst Pharmaceuticals in the 2nd quarter valued at approximately $4,260,000. GSA Capital Partners LLP bought a new stake in shares of Catalyst Pharmaceuticals during the 3rd quarter worth approximately $625,000. Capstone Investment Advisors LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the 3rd quarter worth approximately $708,000. Finally, Allspring Global Investments Holdings LLC increased its stake in Catalyst Pharmaceuticals by 146.8% in the third quarter. Allspring Global Investments Holdings LLC now owns 366,444 shares of the biopharmaceutical company’s stock valued at $7,285,000 after acquiring an additional 217,956 shares during the last quarter. 79.22% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

CPRX has been the subject of several recent research reports. Stephens assumed coverage on Catalyst Pharmaceuticals in a research report on Monday, November 18th. They set an “overweight” rating and a $35.00 price target for the company. Truist Financial upped their price target on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, November 11th. Finally, HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, November 8th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $31.14.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.